Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113463 · ClinicalTrials.gov registry record · Phase 2
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01113463: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01113463 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01113463, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if TPI 287 can help to control glioblastoma. The safety of this drug will also be studied.
Interventions
- DRUG TPI 287
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01113463
The ClinicalTrials.gov registry entry for NCT01113463 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TPI 287 is the first listed.
NCT01113463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01113463 about?
NCT01113463 is a clinical study titled "TPI 287 in Patients With Recurrent Glioblastoma Multiforme". The goal of this clinical research study is to learn if TPI 287 can help to control glioblastoma. The safety of this drug will also be studied.
What is the current status of trial NCT01113463?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2010-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01113463?
The interventions under investigation include: TPI 287 (DRUG).
Who is sponsoring clinical trial NCT01113463?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.